目的：探讨肾性贫血骨髓活组织图像改变。
Objective: To study the change of pathology of bone marrow for renoprival anemia .
已被广泛应用于防止和纠正肾性贫血和非肾性贫血。
It has been used to therapy renal anemia and non-renal anemia.
目的比较静脉注射铁剂和口服铁剂治疗肾性贫血的成本效果。
Objective To evaluate the cost-effectiveness of intravenous and oral iron supplements in hemodialysis patients with chronic renal anemia.
目的观察右旋糖酐铁静脉注射治疗尿毒症致肾性贫血的疗效和不良反应。
Objective to investigate the curative effect and untoward effect of intravenous therapy with iron dextran for renal anemia induced by uremia.
目的：观察肾组织移植对肾性贫血大鼠促红细胞生成素基因表达的影响。
OBJECTIVE: To investigate the effects of kidney tissue allograft transplantation on EPO gene expression in rats with renal anemia.
目的观察静脉补铁治疗维持性血液透析的慢性肾衰患者肾性贫血的效果。
Objective Observer intravenous iron maintenance treatment of chronic kidney hemodialysis patients kidney effects of anaemia.
肾性贫血是尿毒症患者的常见并发症，发生率极高，且为中、重度贫血。
Objective To compare the effects of different erythrocyte preparations on renal anemia in uremic patients.
目的：探讨未成熟网织红细胞指数(IRF)在肾性贫血中的变化及意义。
Objective To explore the changes of immature reticulocyte fraction (IRF) in renal anemia.
目的：探讨促红细胞生成素受体在慢性肾功能衰竭肾性贫血中的表达及意义。
Objective: to study the use of erythropoietin receptor in anemia of chronic renal failure.
本文讨论了PT H水平与钙磷代谢、肾性骨病、肾性贫血、皮肤搔痒的关系。
The relationship between serum PTH and the metabolism of calcium and phosphorus, renal osteopathy, renal anemia and pruritus was discussed.
目的：探讨促红细胞生成素受体（EPOR）在慢性肾功能衰竭肾性贫血中的表达及意义。
Objective: To study the use of erythropoietin receptor (EPOR) in anemia of chronic renal failure.
目的研究电脉冲介导的质粒红细胞生成素(EPO)基因肌肉转移效率以及对肾性贫血的治疗作用。
Objective to investigate the effects of erythropoietin (EPO) gene transfer into skeleton muscle mediated by electroporation on renal anemia.
第一次更新，于2000年出版，描述了一对慢性肾性贫血患者更广泛，其中包括那些没有接受透析。
The first update, published in 2000, described anemia in a wider spectrum of the chronic kidney patients, and included those not on dialysis.
结论：金水宝胶囊具有调节和保护CRF患者红细胞免疫功能的作用，并能改善肾性贫血及改善肾功能。
Conclusions: JSBC possesses regulating and protecting actions on immune functions of RBC in patients with CRF and is able to improve renal anemia and renal functions.
结论静脉组与口服组比较治疗成本没有差别，疗效更好，静脉组治疗肾性贫血更具成本效果，值得临床推荐。
Therefore, intravenous iron dextran has greater cost-effectiveness than oral iron in renal anemia, and is worthy to be recommended to clinical application.
肾性贫血主要是由于肾脏产生红细胞生成素(EPO)不足而引起，这类贫血主要靠补充外源性EPO进行治疗。
Renal anemia is mostly caused by insufficient EPO produced by kidney, which mainly required to be treated with external EPO.
本文就炎症与CRF患者动脉粥样硬化、营养不良、肾性贫血、 促红细胞生成素抵抗等并发症的关系及其治疗进行综述。
The article reviews the relationship between inflammation in patients with CRF and atherosclerosis, malnutrition, renal anemia, resistance of erythropoietin and treatment to inflammation.
结论通过对移植物的形态观察和功能测定，证明肾组织移植是一种有效的治疗手段，有可能为慢性肾性贫血提供一种新的途径。
Conclusion Allograft transplantation of kidney tissue mass can ameliorate renal anemia caused by chronic renal failure and might be a new therapeutic means to treat CRF-induced anemia.
所述尿毒症综合症选自：肾实质损害或肾功能不全引起的氮质血症、肾性高脂血症、肾性贫血以及电解质紊乱导致的尿毒症综合症。
The uremia syndrome includes kidney essence damage or kidney incompetence caused azotemia, renal hyperlipemia, renal anemia and electrolyte disorder caused uremia syndrome.
随后的通常是会导致肝、肾、脾和有时候的心脏病变的溶血性贫血。
This is often followed by hemolytic anemia that can cause liver, kidney, spleen, and sometimes heart effects.
随后的通常是会导致肝、肾、脾和有时候的心脏病变的溶血性贫血。
This is often followed by hemolytic anemia that can cause liver, kidney, spleen, and sometimes heart effects.
应用推荐